RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Back to future againThis phase Ia trial was poorly designed, maybe they were forced into that design by the FDA, and had no other choice, but as I said before, this "all comers" criteria for enrollment was a problem because it introduced potential confusion in the whole thing. If FDA wanted to distinguished the effect of sortilin expression on efficacy and toxicity, it should have been a two arms trial. One with patients with low or no sortilin expression on their tumors, the other arm with high to very high sortilin expression. Instead of that they mixed up everything with no sortilin testing. It was the best way to sow confusion and lead to delays to sort things out before continuing the trial. To me this whole fiasco smells like a company not wanting to lay out publicly their problems with what FDA forced them to do. So they endured until the end of phase Ia and the "all comers" sh*t is over with, and now they can concentrate on patients that fit this trial.